Abstract:Flow chart of patient enrollment and table of EGFR exon 19 deletion (ex19del) variants, with Kaplan–Meier curve for progression free survival (PFS) and overall survival (OS) of first‐line tyrosine kinase inhibitor (TKI) treatment and incidence of secondary T790M mutation, in EGFR ex19del mutations subgroups. (A, B) Comparison of PFS and OS between the classic and nonclassic EGFR ex19del group; (C) PFS in the EGFR ex19del subgroup with deletion starting at E746 accompanying insertion mutation (E746/ins+), comparing with the patients with other ex19del variants; (D, E), comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) tyrosine kinase inhibitor (TKI) in patients with classic EGFR ex19del group; (F, G) comparison of PFS and OS of first‐line therapy with first‐, second‐, and third‐generation (gen.) TKI in patients with nonclassic EGFR ex19del group; (H) incidence of secondary T790M after resistant to first or second generation TKIs, in each subgroup of EGFR ex19del, and comparison between the classic and nonclassic EGFR ex19del groups, between EGFR ex19del subgroups starting at E746 and at other site (ex19del/E746+ vs. ex19del/other site), between EGFR ex19del subgroups with and without insertion mutations (EGFR ex19del/ins+ vs. EGFR ex19del/ins−), and between EGFR ex19del subgroups with deletion length of 15 nucleotides or of other deletion length (ex19del/15+ vs. ex19del/other length). Background Clinical significance of various subtypes of epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) remains unclear. Methods We analyzed EGFR ex19del subtypes in NSCLC patients receiving first‐line tyrosine kinase inhibitor (TKI) therapy at our center (January 2018–June 2022) and correlated them with median progression‐free survival (mPFS) and median overall survival (mOS). Results We identified 17 different EGFR ex19del variants in 101 patients. Between the classic (E746_A750del, 64.4%) and nonclassic groups (the rest variants), no significant difference was observed in mPFS (13.5 vs. 19.3 months, p = 0.18) or mOS (44.1 vs. 77.0 months, p = 0.06). mPFS showed no significant difference between ex19del subgroups classified based on the presence of insertion (ex19delins), starting position or length of deletion. However, patients with ex19delins starting at E746 showed longer mPFS than the others (29.7 vs. 12.5 months, p = 0.04), and patients with ex19del of 15 nucleotides had shorter mOS than the others (44.1 vs. 77.0 months, p = 0.03). In multivariate analysis, ex19delins independently predicted a better PFS (HR = 0.311, p = 0.03); however, 15 nucleotide deletion was no longer associated with OS (HR = 0.181, p = 0.11). Secondary T790M mutation incidence was significantly higher in the ex19del subgroup starting at E746 than the others (64.7% vs. 30.8%, p = 0.04). Conclusions Our study revealed potential differences in TKI efficacy, resistance mechanism, and prognosis of various EGFR ex19del subtypes in NSCLC, underscoring the need for precise selection of first‐line therapy.

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Effect of EGFR amplification on survival of patients with EGFR mutation-positive non-small cell lung cancer.

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions

Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer

Better Survival with Epidermal Growth Factor Receptor Exon 19 Deletion Than with Exon 21 Mutation in Gefitinib-Treated Non-Small Cell Lung Cancer Patients is Due to Differential Inhibition of Downstream Signals

[The Association Between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A Meta-Analysis.].

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and Its Response to EGFR-TKIs

[Clinicopathological Features Associated with EGFR Gene Mutation in Non-Small Cell Lung Cancer Patients].

Real-world Response and Outcomes in Patients with NSCLC with EGFR Exon 20 Insertion Mutations

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center ambispective cohort study

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen

Clinical Outcomes of EGFR-TKI Treatment and Genetic Heterogeneity in Lung Adenocarcinoma Patients with EGFR Mutations on Exons 19 and 21

EGFR exon 20 insertion mutations in non-small cell lung cancer

Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases

Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions

Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors.

The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma

Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer; Single-Institution Experience

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

EGFR Exon20 Insertion Mutations in Non-Small Cell Lung Cancer: Clinical Implications and Recent Advances in Targeted Therapies.

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives